Clinical trial

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

NCT05998993

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-11-01

PhaseNA

Study timeline

Study start (estimated)2023-11-01Date precision: month

Registry last updated2023-08-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

EGF-R Positive Non-Small Cell Lung Cancerunresolved

Non Small Cell Lung Cancerunresolved

EGFR Exon 19 Deletionunresolved

EGFR Exon 21 Mutationunresolved

EGFR G719Xunresolved

Interventions

Stereotactic Body Radiation Therapy SBRTRADIATION

Sponsors & collaborators

Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulolead sponsor

Mapped research locations

BogotáColombia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05998993 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.